Nocita (bupivacaine liposome)

Nocita is an FDA-approved veterinary local anesthetic containing bupivacaine encapsulated in liposomes, designed to provide extended post-operative pain relief in dogs for up to 72 hours following a single administration. This innovative formulation represents a significant advancement in veterinary pain management by addressing the challenge of prolonged post-surgical analgesia without requiring repeated dosing or continuous infusion systems. Nocita was specifically developed and approved for veterinary use, making it one of the few extended-release local anesthetic products designed exclusively for animal patients. The product was initially approved for use in dogs undergoing cranial cruciate ligament surgery and has become an important component of multimodal analgesia protocols for orthopedic procedures.

The mechanism of action of Nocita is based on the local anesthetic properties of bupivacaine, which blocks sodium channels in nerve membranes to prevent the generation and conduction of pain signals. What distinguishes Nocita from standard bupivacaine formulations is its DepoFoam technology, which encapsulates bupivacaine within multivesicular liposomes. These microscopic lipid-based particles gradually release bupivacaine over an extended period, maintaining therapeutic drug concentrations at the surgical site for up to 72 hours. This sustained release profile provides prolonged analgesia during the most painful portion of the post-operative period without requiring additional local anesthetic injections or systemic analgesics.

Nocita is supplied as a sterile injectable suspension specifically formulated for local infiltration at surgical sites. The product comes in single-use vials and requires specific handling to maintain the integrity of the liposomal structure. Unlike standard bupivacaine solutions, Nocita should not be diluted, mixed with other drugs, or administered through fine needles that could disrupt the liposomes. The suspension is administered by infiltration into the surgical site tissues at the time of wound closure, where it creates a depot of slow-release local anesthetic. The product's viscosity differs from standard local anesthetic solutions, and administration technique should follow manufacturer guidelines.

The safety profile of Nocita has been established through FDA-required clinical trials in dogs, demonstrating both efficacy and tolerability when used according to labeled instructions. As a veterinary-specific product, Nocita addresses the unique needs of canine patients, including the challenge of providing sustained analgesia in animals that cannot self-report pain or request additional medication. Veterinary supervision is essential for Nocita use, as proper patient selection, dosing, and administration technique are critical for achieving optimal analgesic outcomes. When incorporated into a comprehensive pain management plan, Nocita can significantly improve post-operative comfort and recovery quality for canine surgical patients.

The primary FDA-approved indication for Nocita in dogs is the provision of local post-operative analgesia for cranial cruciate ligament (CCL) surgery, one of the most commonly performed orthopedic procedures in veterinary medicine. Cranial cruciate ligament rupture causes significant pain and disability, and surgical repair procedures such as tibial plateau leveling osteotomy (TPLO), tibial tuberosity advancement (TTA), and lateral suture stabilization involve substantial tissue manipulation and bone work. Nocita is administered by infiltration into the tissues of the surgical site during wound closure, providing extended pain relief during the critical first 72 hours of recovery when post-operative pain is typically most intense.

The extended duration of action provided by Nocita addresses a significant challenge in veterinary orthopedic surgery, specifically the need for sustained analgesia in the immediate post-operative period. Traditional local anesthetics like bupivacaine provide analgesia for four to eight hours, after which patients require additional pain management through systemic medications. Nocita's 72-hour duration covers the period when surgical site pain is most severe, reducing the reliance on opioids and other systemic analgesics that may cause sedation, gastrointestinal effects, or other undesirable side effects. This supports better patient comfort, more normal eating and activity, and potentially faster recovery.

While the FDA approval for Nocita in dogs specifically mentions cranial cruciate ligament surgery, veterinarians may use the product for other orthopedic and soft tissue surgical procedures based on clinical judgment. Off-label applications may include other orthopedic surgeries such as fracture repair, joint surgeries, and limb amputations, as well as major soft tissue procedures including mass removals, abdominal surgeries, and thoracic procedures. The principle of using Nocita for procedures expected to cause significant post-operative pain, where extended local analgesia would benefit the patient, guides these clinical decisions.

Nocita serves as a component of multimodal analgesia protocols rather than a standalone pain management solution. Post-operative pain involves multiple mechanisms and pathways, and optimal pain control typically requires addressing pain through complementary approaches. Nocita provides local anesthetic blockade at the surgical site, while other components of a multimodal protocol may include non-steroidal anti-inflammatory drugs for inflammation-mediated pain, opioids for breakthrough pain, and adjunctive analgesics as needed. The addition of Nocita to these protocols enhances overall pain control and may reduce the doses of systemic analgesics required.

The decision to use Nocita involves consideration of patient factors, surgical procedure, and overall anesthetic plan. Nocita is particularly valuable for procedures where post-operative pain is expected to be significant and prolonged, where patient compliance with oral medication administration may be challenging, or where minimizing systemic analgesic use is desirable. Veterinary surgeons incorporate Nocita into their pain management planning during the pre-operative phase, ensuring the product is available and that administration can be incorporated smoothly into the surgical workflow.

Nocita dosing is based on the volume of tissue to be infiltrated rather than strict weight-based calculations, though maximum dose limits based on body weight apply. For cranial cruciate ligament surgery in dogs, the labeled dose is 5.3 mg/kg (0.4 mL/kg) of body weight, administered as a single dose by infiltration into the surgical site. The total dose is divided and administered into the tissues surrounding the surgical site, including the joint capsule, surrounding musculature, and subcutaneous tissues. The veterinary surgeon calculates the appropriate volume based on patient weight and plans the distribution of the suspension throughout the relevant tissue layers.

Administration technique for Nocita differs from standard local anesthetic injection due to the liposomal formulation. The product should not be diluted, as dilution may disrupt the liposomal structure and alter the release characteristics. Nocita should not be mixed with other medications in the same syringe or administered through the same needle used for other products. An 18-gauge or larger needle is recommended to prevent shearing of the liposomes during injection. The suspension should be gently inverted to resuspend the particles before withdrawal and administration, but vigorous shaking should be avoided.

The timing of Nocita administration is typically at the completion of surgery, immediately before or during wound closure. This timing allows the suspension to be deposited into the tissues that will generate post-operative pain signals, including the surgically manipulated structures and the incision site. The veterinary surgeon infiltrates the suspension in small aliquots through multiple injection points to distribute the medication throughout the relevant tissue layers. The volume per injection site varies based on the anatomy and the surgeon's technique, with the goal of achieving broad tissue coverage while maintaining the suspension within the target area.

Nocita is provided in single-use vials, and any unused portion should be discarded rather than saved for future use. The product should be stored in the refrigerator at 2°C to 8°C (36°F to 46°F) before use. Vials should be removed from refrigeration and allowed to reach room temperature before administration. The suspension should be inspected before use to ensure there is no particulate matter, discoloration, or other abnormality that would indicate product degradation. Proper handling preserves the integrity of the liposomal structure that is essential for the extended-release profile.

Because Nocita provides analgesia at the local tissue level, it does not replace the need for adequate intraoperative anesthesia or immediate post-operative systemic analgesia. The onset of action occurs as the liposomes begin releasing bupivacaine, but peak tissue concentrations develop gradually over hours rather than minutes. Patients should receive appropriate systemic analgesia in the immediate post-operative period, with the Nocita providing sustained background analgesia that reduces overall analgesic requirements over the following 72 hours.

Post-operative monitoring should assess the patient's comfort level and response to the multimodal analgesic protocol. While Nocita provides extended local analgesia, some patients may require additional systemic pain medication, particularly during the first few hours after surgery before the full analgesic effect develops, or if the surgical procedure was particularly extensive. The veterinary team evaluates each patient individually and adjusts the pain management plan as needed to ensure adequate comfort during recovery.

Nocita has demonstrated a favorable safety profile in clinical trials and post-market experience when administered according to labeled guidelines. The product was developed specifically for veterinary use and underwent FDA evaluation for both efficacy and safety in dogs undergoing cranial cruciate ligament surgery. Most dogs tolerate Nocita well, with the extended local analgesia providing significant benefits for post-operative comfort. However, as with any medication, adverse effects are possible, and awareness of potential reactions enables appropriate patient monitoring.

Local reactions at the injection site are among the most commonly reported effects and may include swelling, bruising, or discharge from the surgical wound. In clinical trials, dogs receiving Nocita showed similar rates of incisional complications compared to control groups, suggesting that most local effects may be related to the surgery itself rather than specifically to the medication. Inflammation at the injection site is occasionally observed and typically resolves without specific treatment. Surgical site infections, while not caused by Nocita, should be monitored for as with any surgical procedure.

Systemic effects from Nocita are uncommon due to the slow release of bupivacaine from the liposomal formulation, which maintains local tissue concentrations while minimizing systemic absorption. However, if significant systemic absorption were to occur, effects consistent with bupivacaine toxicity could theoretically develop. These would include central nervous system effects such as tremors, restlessness, or seizures, and cardiovascular effects such as bradycardia, arrhythmias, or hypotension. The sustained-release mechanism of Nocita is designed to prevent the rapid systemic absorption that causes these effects with standard bupivacaine formulations.

Delayed wound healing has been observed occasionally in patients receiving Nocita, though establishing a causal relationship is complicated by the concurrent surgical procedure and other factors affecting wound healing. Veterinarians should monitor surgical sites for appropriate healing and address any wound complications according to standard protocols. In clinical studies, rates of delayed healing and other wound complications were similar between Nocita-treated dogs and controls, suggesting the product does not significantly impair normal wound healing when used appropriately.

Allergic reactions to Nocita are possible, as with any medication. Dogs with known hypersensitivity to bupivacaine or other amide-type local anesthetics should not receive Nocita. Signs of allergic reaction may include facial swelling, hives, or more severe anaphylactic responses. Any suspected allergic reaction should be reported to the veterinarian immediately. If a dog has previously tolerated other amide local anesthetics without reaction, the risk of allergy to Nocita is low, but vigilance is still appropriate.

The primary contraindication for Nocita is known hypersensitivity to bupivacaine or any other amide-type local anesthetic. Dogs that have experienced allergic reactions to lidocaine, mepivacaine, ropivacaine, or bupivacaine should not receive Nocita due to potential cross-reactivity within the amide local anesthetic class. Additionally, hypersensitivity to any component of the Nocita formulation, including the lipid components of the liposomal delivery system, would contraindicate its use. Pet owners should inform the veterinary team of any known drug allergies or previous adverse reactions to local anesthetics before surgery.

Nocita should not be administered by intravenous, intra-arterial, or intrathecal routes. The product is specifically formulated for local tissue infiltration, and systemic administration could result in severe cardiovascular and neurological toxicity. Accidental intravascular injection during local infiltration should be avoided through careful aspiration before injection. The product should also not be used for regional nerve blocks or epidural administration, as the liposomal formulation is not designed for these applications and may not provide appropriate drug release profiles or could cause local tissue effects.

Use of Nocita in dogs with known significant hepatic impairment requires careful consideration, as bupivacaine is metabolized primarily in the liver. While the slow release from the liposomal formulation results in lower peak plasma concentrations than standard bupivacaine injections, impaired hepatic function could still affect drug clearance and increase the risk of accumulation. Veterinarians should weigh the benefits of extended local analgesia against potential risks in dogs with liver disease and may choose alternative analgesic approaches in patients with severe hepatic dysfunction.

The safety of Nocita has not been established in dogs used for breeding purposes, or in pregnant or lactating dogs. The product should be used with caution in these populations, with the veterinarian determining whether the benefits of extended post-operative analgesia justify any potential risks. Similarly, while Nocita has been used in dogs of various ages, specific studies in very young puppies have not been conducted, and the product should be used judiciously in pediatric patients with consideration of their developing physiology.

Comprehensive disclosure of all medications your dog receives is essential before Nocita administration. While the liposomal formulation of Nocita results in slow, controlled release of bupivacaine that minimizes systemic drug levels, potential interactions with other medications should still be considered. The veterinary team uses this information to optimize the overall anesthetic and analgesic plan while minimizing interaction risks.

Other local anesthetics are the most important class of medications to consider when using Nocita. If standard bupivacaine or other local anesthetics are used during the same procedure, such as for regional nerve blocks or intraoperative analgesia, the total dose of all local anesthetic agents should be calculated to prevent cumulative toxicity. While Nocita's slow release minimizes its contribution to peak plasma levels, the sustained duration means that bupivacaine from Nocita will be present in tissues for days, which should be considered if additional local anesthetic procedures are needed during the recovery period.

Class I antiarrhythmic drugs such as mexiletine and lidocaine share similar mechanisms of action with bupivacaine and could theoretically have additive cardiac effects if significant systemic absorption of Nocita occurred. While this interaction is unlikely to be clinically relevant with proper Nocita administration, dogs receiving antiarrhythmic medications should be monitored appropriately after surgery. Beta-blockers and calcium channel blockers may also potentiate cardiovascular effects of bupivacaine if systemic levels become elevated.

Drugs affecting hepatic metabolism may influence the clearance of bupivacaine as it is gradually released from the liposomal formulation. Medications that inhibit cytochrome P450 enzymes, particularly CYP3A4, could reduce bupivacaine metabolism and prolong its effects. Conversely, enzyme-inducing drugs might accelerate clearance. The clinical significance of these interactions with Nocita is likely limited due to the low systemic concentrations achieved with local administration, but veterinarians consider concurrent medications when evaluating overall patient management.

General precautions for Nocita use begin with appropriate patient selection and surgical planning. The product is indicated for local infiltration at surgical sites, and its benefits are greatest for procedures where extended post-operative pain is anticipated. Accurate body weight measurement is essential for dose calculation, and the maximum recommended dose should not be exceeded. The veterinary team ensures that proper administration technique is used, including appropriate needle gauge, avoidance of dilution, and distribution of the suspension throughout the relevant tissue layers.

Breed-specific considerations for Nocita are not well-documented, as the FDA approval studies did not identify specific breed-related safety concerns. The MDR1 (ABCB1) gene mutation present in many herding breeds does not appear to significantly affect local anesthetics like bupivacaine. However, as with all medications in dogs, individual variation in response is possible, and monitoring is appropriate in all patients. Brachycephalic breeds may have specific anesthetic considerations unrelated to Nocita that should be addressed in overall anesthetic planning.

Handling and administration precautions are particularly important for Nocita due to its unique liposomal formulation. The product must be stored refrigerated and allowed to reach room temperature before use. Vials should be gently inverted to resuspend the particles, avoiding vigorous shaking that could damage the liposomes. An 18-gauge or larger needle prevents shearing of liposomes during withdrawal and injection. The product should not be diluted, filtered, or mixed with other medications. Single-use vials should not be saved for later use, and any unused portion should be discarded according to facility protocols.

Monitoring during the post-operative period includes assessment of both surgical site healing and pain control. The surgical incision should be observed for signs of normal healing versus complications such as excessive swelling, discharge, or delayed closure. Pain assessment using validated tools should be performed regularly to ensure the patient remains comfortable. While Nocita provides extended local analgesia, it is part of a multimodal protocol, and systemic analgesics should be adjusted based on individual patient needs. Dogs should be restricted from excessive activity that could stress the surgical site during the recovery period.

Special populations requiring additional consideration include geriatric dogs, who may have decreased organ function affecting drug metabolism and clearance. Dogs with pre-existing cardiovascular disease should be monitored for any signs of cardiac effects, though the slow-release formulation makes significant cardiovascular effects unlikely with proper administration. Debilitated or cachectic dogs may have altered drug distribution and should be dosed conservatively. The veterinary surgeon evaluates each patient's overall health status when incorporating Nocita into the pain management plan.

Nocita requires refrigerated storage at 2°C to 8°C (36°F to 46°F) prior to use. The product should be kept in its original packaging to protect from light until ready for use. Unlike many injectable medications that are stable at room temperature, Nocita's liposomal formulation requires cold storage to maintain the integrity of the lipid-based delivery system. Veterinary facilities should designate appropriate refrigerator space for Nocita storage and implement inventory management to ensure proper storage conditions are maintained.

Before administration, Nocita vials should be removed from refrigeration and allowed to reach room temperature. This typically takes 30 to 60 minutes depending on ambient conditions. Using cold product may affect the properties of the suspension and patient comfort during injection. The vial should be gently inverted multiple times to resuspend the liposomal particles before withdrawing the dose, as settling may occur during storage. Vigorous shaking should be avoided, as this could damage the liposomal structure and alter the drug release profile. Visual inspection should confirm that the suspension appears uniform without clumping, discoloration, or particulate matter.

Nocita is supplied in single-use vials, and any unused portion must be discarded after the dose is withdrawn. The liposomal formulation does not contain preservatives that would allow safe storage after opening. Unused product and empty vials should be disposed of according to local regulations for pharmaceutical waste. Given the refrigeration requirements, veterinary facilities typically order Nocita in quantities appropriate for anticipated use to minimize waste from expiration while ensuring availability when needed for surgical patients. Expired product should never be used, as degradation of the liposomal structure could affect both efficacy and safety.

Most dogs tolerate Nocita well regardless of breed when administered according to labeled guidelines. The FDA approval studies for Nocita included dogs of various breeds undergoing cranial cruciate ligament surgery, and no breed-specific safety concerns were identified. The primary considerations for Nocita use relate to the surgical procedure, patient size, and overall health status rather than breed-specific genetic factors. Nevertheless, understanding how breed characteristics might influence the surgical and recovery experience helps optimize outcomes.

The MDR1 (ABCB1) gene mutation, which affects drug metabolism in Collies, Australian Shepherds, Shetland Sheepdogs, Border Collies, and related herding breeds, is not known to significantly impact bupivacaine handling. Local anesthetics are not recognized substrates for the P-glycoprotein transporter encoded by the MDR1 gene. Therefore, dogs with MDR1 mutations do not require specific dose adjustments for Nocita based on this genetic variation. However, these breeds may have sensitivities to other medications used in anesthetic protocols, and the veterinary anesthesiologist plans the overall approach accordingly.

Size considerations apply to Nocita as with other local anesthetics. Large and giant breed dogs such as Great Danes, Saint Bernards, and Mastiffs undergoing orthopedic surgery may require the maximum labeled dose and benefit significantly from extended post-operative analgesia given the magnitude of surgical procedures in these patients. Small and toy breed dogs require accurate dose calculation based on precise weight measurement. While cranial cruciate ligament surgery is less common in very small dogs, Nocita may be used for other procedures in these patients, requiring careful attention to volume and distribution of the suspension.

Certain breed predispositions to cruciate ligament disease are worth noting, as these dogs are common candidates for Nocita use. Labrador Retrievers, Golden Retrievers, Rottweilers, and other large breeds have elevated incidence of cranial cruciate ligament rupture. These breeds are frequently represented in TPLO and similar surgical populations and have provided substantial real-world experience with Nocita use. Age-related considerations, including the tendency for orthopedic conditions to affect middle-aged and older dogs, mean that many Nocita recipients are mature animals with potential for concurrent health conditions. The veterinary team evaluates each patient comprehensively when planning surgery and pain management.

Standard bupivacaine formulations remain available as alternatives when extended-release analgesia is not needed or when Nocita is not available. Conventional bupivacaine provides four to eight hours of local analgesia after injection, which may be adequate for minor procedures or when combined with other analgesic approaches for more significant surgeries. Lidocaine offers faster onset but shorter duration, typically one to two hours, and may be used for initial anesthesia or when prolonged effect is not required. Ropivacaine provides an alternative amide local anesthetic with a duration similar to bupivacaine and a somewhat improved cardiovascular safety profile.

Systemic analgesics form essential components of multimodal pain management protocols alongside Nocita. Non-steroidal anti-inflammatory drugs such as carprofen, meloxicam, and robenacoxib address inflammation-mediated pain and are commonly included in post-operative protocols for orthopedic surgery. Opioid analgesics including hydromorphone, morphine, and buprenorphine provide additional pain control, particularly in the immediate post-operative period before Nocita reaches full effect. Adjunctive medications such as gabapentin may address neuropathic components of surgical pain. The combination of Nocita with these systemic agents provides comprehensive pain control through multiple mechanisms.

Non-pharmacological approaches complement medication-based pain management for surgical patients. Physical rehabilitation, including passive range of motion exercises and controlled activity, supports recovery and can reduce pain associated with muscle stiffness and atrophy. Cold therapy in the early post-operative period helps control inflammation and provides analgesic effects. Weight management is essential for dogs recovering from cruciate ligament surgery, as excess body weight increases stress on the healing joint. The veterinary team develops comprehensive recovery plans that integrate Nocita with other analgesic modalities and supportive care measures, and any modifications to prescribed protocols should be made only under professional guidance.